Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine Augmentation in SSRI-Resistant MDD
NCT00733668Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of quetiapine (extended-release tablet, brand name: Bipresso) in major depressive disorder (MDD), sponsored by AstraZeneca. Started Mar 2006; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00733668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00733668.